182 related articles for article (PubMed ID: 14871245)
41. Discovery of JSI-124 (cucurbitacin I), a selective Janus kinase/signal transducer and activator of transcription 3 signaling pathway inhibitor with potent antitumor activity against human and murine cancer cells in mice.
Blaskovich MA; Sun J; Cantor A; Turkson J; Jove R; Sebti SM
Cancer Res; 2003 Mar; 63(6):1270-9. PubMed ID: 12649187
[TBL] [Abstract][Full Text] [Related]
42. Constitutively activated FGFR3 mutants signal through PLCgamma-dependent and -independent pathways for hematopoietic transformation.
Chen J; Williams IR; Lee BH; Duclos N; Huntly BJ; Donoghue DJ; Gilliland DG
Blood; 2005 Jul; 106(1):328-37. PubMed ID: 15784730
[TBL] [Abstract][Full Text] [Related]
43. The inhibitory anti-FGFR3 antibody, PRO-001, is cytotoxic to t(4;14) multiple myeloma cells.
Trudel S; Stewart AK; Rom E; Wei E; Li ZH; Kotzer S; Chumakov I; Singer Y; Chang H; Liang SB; Yayon A
Blood; 2006 May; 107(10):4039-46. PubMed ID: 16467200
[TBL] [Abstract][Full Text] [Related]
44. Functional significance of novel neurotrophin-1/B cell-stimulating factor-3 (cardiotrophin-like cytokine) for human myeloma cell growth and survival.
Burger R; Bakker F; Guenther A; Baum W; Schmidt-Arras D; Hideshima T; Tai YT; Shringarpure R; Catley L; Senaldi G; Gramatzki M; Anderson KC
Br J Haematol; 2003 Dec; 123(5):869-78. PubMed ID: 14632778
[TBL] [Abstract][Full Text] [Related]
45. FGFR3 dysregulation in multiple myeloma: frequency and prognostic relevance.
Rasmussen T; Hudlebusch HR; Knudsen LM; Johnsen HE
Br J Haematol; 2002 Jun; 117(3):626-8. PubMed ID: 12028033
[TBL] [Abstract][Full Text] [Related]
46. MIP-1alpha (CCL3) is a downstream target of FGFR3 and RAS-MAPK signaling in multiple myeloma.
Masih-Khan E; Trudel S; Heise C; Li Z; Paterson J; Nadeem V; Wei E; Roodman D; Claudio JO; Bergsagel PL; Stewart AK
Blood; 2006 Nov; 108(10):3465-71. PubMed ID: 16849642
[TBL] [Abstract][Full Text] [Related]
47. HIV-1 protease inhibitor induces growth arrest and apoptosis of human multiple myeloma cells via inactivation of signal transducer and activator of transcription 3 and extracellular signal-regulated kinase 1/2.
Ikezoe T; Saito T; Bandobashi K; Yang Y; Koeffler HP; Taguchi H
Mol Cancer Ther; 2004 Apr; 3(4):473-9. PubMed ID: 15078991
[TBL] [Abstract][Full Text] [Related]
48. Bortezomib therapeutic effect is associated with expression of FGFR3 in multiple myeloma cells.
Guan M; Zhu L; Somlo G; Hughes A; Zhou B; Yen Y
Anticancer Res; 2009 Jan; 29(1):1-9. PubMed ID: 19331127
[TBL] [Abstract][Full Text] [Related]
49. Accelerated proliferation of myeloma cells by interleukin-6 cooperating with fibroblast growth factor receptor 3-mediated signals.
Ishikawa H; Tsuyama N; Liu S; Abroun S; Li FJ; Otsuyama K; Zheng X; Ma Z; Maki Y; Iqbal MS; Obata M; Kawano MM
Oncogene; 2005 Sep; 24(41):6328-32. PubMed ID: 15940250
[TBL] [Abstract][Full Text] [Related]
50. Frequent translocation t(4;14)(p16.3;q32.3) in multiple myeloma is associated with increased expression and activating mutations of fibroblast growth factor receptor 3.
Chesi M; Nardini E; Brents LA; Schröck E; Ried T; Kuehl WM; Bergsagel PL
Nat Genet; 1997 Jul; 16(3):260-4. PubMed ID: 9207791
[TBL] [Abstract][Full Text] [Related]
51. The novel JAK inhibitor AZD1480 blocks STAT3 and FGFR3 signaling, resulting in suppression of human myeloma cell growth and survival.
Scuto A; Krejci P; Popplewell L; Wu J; Wang Y; Kujawski M; Kowolik C; Xin H; Chen L; Wang Y; Kretzner L; Yu H; Wilcox WR; Yen Y; Forman S; Jove R
Leukemia; 2011 Mar; 25(3):538-50. PubMed ID: 21164517
[TBL] [Abstract][Full Text] [Related]
52. Expression of interferon alfa signaling components in human alcoholic liver disease.
Nguyen VA; Gao B
Hepatology; 2002 Feb; 35(2):425-32. PubMed ID: 11826419
[TBL] [Abstract][Full Text] [Related]
53. Inhibition of signal transducer and activator transcription factor 3 in rats with acute hepatic failure.
Kamohara Y; Sugiyama N; Mizuguchi T; Inderbitzin D; Lilja H; Middleton Y; Neuman T; Demetriou AA; Rozga J
Biochem Biophys Res Commun; 2000 Jun; 273(1):129-35. PubMed ID: 10873574
[TBL] [Abstract][Full Text] [Related]
54. In multiple myeloma, t(4;14)(p16;q32) is an adverse prognostic factor irrespective of FGFR3 expression.
Keats JJ; Reiman T; Maxwell CA; Taylor BJ; Larratt LM; Mant MJ; Belch AR; Pilarski LM
Blood; 2003 Feb; 101(4):1520-9. PubMed ID: 12393535
[TBL] [Abstract][Full Text] [Related]
55. The thanatophoric dysplasia type II mutation hampers complete maturation of fibroblast growth factor receptor 3 (FGFR3), which activates signal transducer and activator of transcription 1 (STAT1) from the endoplasmic reticulum.
Lievens PM; Liboi E
J Biol Chem; 2003 May; 278(19):17344-9. PubMed ID: 12624096
[TBL] [Abstract][Full Text] [Related]
56. FGFR3 is expressed and is important for survival in INA-6, a human myeloma cell line without a t(4;14).
Våtsveen TK; Brenne AT; Dai HY; Waage A; Sundan A; Børset M
Eur J Haematol; 2009 Nov; 83(5):471-6. PubMed ID: 19594619
[TBL] [Abstract][Full Text] [Related]
57. TNF-alpha induces tyrosine phosphorylation and recruitment of the Src homology protein-tyrosine phosphatase 2 to the gp130 signal-transducing subunit of the IL-6 receptor complex.
Bode JG; Schweigart J; Kehrmann J; Ehlting C; Schaper F; Heinrich PC; Häussinger D
J Immunol; 2003 Jul; 171(1):257-66. PubMed ID: 12817006
[TBL] [Abstract][Full Text] [Related]
58. Janus kinase inhibitor INCB20 has antiproliferative and apoptotic effects on human myeloma cells in vitro and in vivo.
Burger R; Le Gouill S; Tai YT; Shringarpure R; Tassone P; Neri P; Podar K; Catley L; Hideshima T; Chauhan D; Caulder E; Neilan CL; Vaddi K; Li J; Gramatzki M; Fridman JS; Anderson KC
Mol Cancer Ther; 2009 Jan; 8(1):26-35. PubMed ID: 19139110
[TBL] [Abstract][Full Text] [Related]
59. The farnesyltransferase inhibitor L744832 potentiates UCN-01-induced apoptosis in human multiple myeloma cells.
Pei XY; Dai Y; Rahmani M; Li W; Dent P; Grant S
Clin Cancer Res; 2005 Jun; 11(12):4589-600. PubMed ID: 15958645
[TBL] [Abstract][Full Text] [Related]
60. Structure and function of a new STAT-induced STAT inhibitor.
Naka T; Narazaki M; Hirata M; Matsumoto T; Minamoto S; Aono A; Nishimoto N; Kajita T; Taga T; Yoshizaki K; Akira S; Kishimoto T
Nature; 1997 Jun; 387(6636):924-9. PubMed ID: 9202127
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
